Inhibition of Pseudomonas aeruginosa PAO1 adhesion to and invasion of A549 lung epithelial cells by natural extractsAHMED, Ghada F; ELKHATIB, Walid F; NOREDDIN, Ayman M et al.Journal of infection and public health (Print). 2014, Vol 7, Num 5, pp 436-444, issn 1876-0341, 9 p.Article

Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia : pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniaeNOREDDIN, Ayman M; HOBAN, Daryl J; ZHANEL, George G et al.International journal of antimicrobial agents. 2005, Vol 26, Num 2, pp 120-125, issn 0924-8579, 6 p.Article

Comparative Pharmacodynamics of Garenoxacin, Gemifloxacin, and Moxifloxacin in Community-Acquired Pneumonia Caused by Streptococcus pneumoniae : A Monte Carlo Simulation AnalysisNOREDDIN, Ayman M; REESE, Angela A; OSTROSKI, Melissa et al.Clinical therapeutics. 2007, Vol 29, Num 12, pp 2685-2689, issn 0149-2918, 5 p.Article

Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across CanadaZHANEL, George G; WALKTY, Andrew; NICHOL, Kim et al.Diagnostic microbiology and infectious disease. 2003, Vol 45, Num 1, pp 63-67, issn 0732-8893, 5 p.Article

The ketolides: A critical reviewZHANEL, George G; WALTERS, Michael; NOREDDIN, Ayman et al.Drugs (Basel). 2002, Vol 62, Num 12, pp 1771-1804, issn 0012-6667, 34 p.Article

Comparative review of the carbapenemsZHANEL, George G; WIEBE, Ryan; DILAY, Leanne et al.Drugs (Basel). 2007, Vol 67, Num 7, pp 1027-1052, issn 0012-6667, 26 p.Article

Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP)NOREDDIN, Ayman M; MARRAS, Theodore K; SANDERS, Kevin et al.International journal of antimicrobial agents. 2004, Vol 24, Num 5, pp 479-484, issn 0924-8579, 6 p.Article

Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniaeZHANEL, George G; JAMES, Joanne; DERKATCH, Sheldon et al.Journal of antimicrobial chemotherapy (Print). 2006, Vol 58, Num 1, pp 112-116, issn 0305-7453, 5 p.Article

Antibiotic resistance in Escherichia coli outpatient urinary isolates : final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)ZHANEL, George G; HISANAGA, Tamiko L; HOBAN, Daryl J et al.International journal of antimicrobial agents. 2006, Vol 27, Num 6, pp 468-475, issn 0924-8579, 8 p.Article

The glycylcyclines: A comparative review with the tetracyclinesZHANEI, George G; HOMENUIK, Kristen; NICHOL, Kim et al.Drugs (Basel). 2004, Vol 64, Num 1, pp 63-88, issn 0012-6667, 26 p.Article

Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrationsZHANEL, George G; DECORBY, Mel; NOREDDIN, Ayman et al.Journal of antimicrobial chemotherapy (Print). 2003, Vol 52, Num 1, pp 83-88, issn 0305-7453, 6 p.Article

Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniaeZHANEL, George G; ROBERTS, Danielle; WALTKY, Andrew et al.Journal of antimicrobial chemotherapy (Print). 2002, Vol 49, Num 5, pp 807-812, issn 0305-7453Article

Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro modelZHANEL, George G; ROSSNAGEL, Emma; NICHOL, Kim et al.Journal of antimicrobial chemotherapy (Print). 2011, Vol 66, Num 6, pp 1301-1305, issn 0305-7453, 5 p.Article

Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic modelZHANEL, George G; YACHISON, Chris; NICHOL, Kim et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 7, pp 1706-1711, issn 0305-7453, 6 p.Article

Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro modelZHANEL, George G; VOTH, Dylan; NICHOL, Kim et al.Journal of antimicrobial chemotherapy (Print). 2009, Vol 64, Num 2, pp 364-369, issn 0305-7453, 6 p.Article

Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(b)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrationsNOREDDIN, Ayman M; ROBERTS, Danielle; NICHOL, Kim et al.Antimicrobial agents and chemotherapy. 2002, Vol 46, Num 12, pp 4029-4034, issn 0066-4804, 6 p.Article

A Review of a Broad-Spectrum and Anti-MRSA CephalosporinZHANEL, George G; LAM, Ashley; SCHWEIZER, Frank et al.American journal of clinical dermatology. 2008, Vol 9, Num 4, pp 245-254, issn 1175-0561, 10 p.Article